Semaglutide use may be increasing worldwide rates of ischemic optic neuropathy and retinal adverse events, a study suggests.

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Variants of obesity-related genes influence how much weight patients lose on specific weight loss drugs like liraglutide, two studies report.

GLP-1 drugs such as Wegovy, Ozempic and Mounjaro are transforming weight loss and reshaping the food industry - driving ...

GLP-1RAs were associated with improved quality of life and emotional eating behaviors among individuals with overweight and obesity.

Losing weight and sustaining a healthy weight are notoriously difficult. If you’re struggling to reach your weight goals, you ...

A Growing Double BurdenThe rising prevalence of prediabetes and chronic kidney disease (CKD) in India reflects an ...

A new study found a link between GLP-1s and a higher risk of neovascular age-related macular degeneration, an eye disease ...

Coming off a successful initial public offering, Omada Health President Wei-Li Shao said the company is focused on turning a ...

The following is a summary of “Association of Glucagon-like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.